國家衛生研究院 NHRI:Item 3990099045/4543
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 909775      線上人數 : 866
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4543


    題名: Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer
    作者: Chen, YM;Wu, MF;Perng, RP;Chou, CM;Yang, KY;Lin, WC;Tsai, CM;Liu, JM;WhangPeng, J
    貢獻者: National Institute of Cancer Research
    摘要: We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity, Between January 1994 and December 1995, 16 patients were treated, Ifosfamide and etoposide doses were ifosfamide 2 g/m(2), with mesna, i,v, infusion over 30 minutes on days 1-3 and etoposide 80 mg/m(2) i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles, All patients were evaluable for toxicity profile and treatment response, As expected, the major toxicity was myelosuppression, With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7% of the total courses had grade 3 or 4 leukopenia, Nine of 16 patients (56.3%) experienced episodes of febrile neutropenia, One toxic death due to febrile neutropenia with sepsis was documented, Toxicities other than leukopenia were few and mild in severity, After two cycles of treatment, the overall response rate was 81.3% (95% confidence interval 62.2-100) in this study, The median duration of response was 8 months and median survival was 11 months, In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.
    日期: 1997-04
    關聯: Japanese Journal of Clinical Oncology. 1997 Apr;27(2):76-79.
    Link to: http://jjco.oxfordjournals.org/cgi/content/abstract/27/2/76
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0368-2811&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:A1997WX68200004
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0031110127
    顯示於類別:[彭汪嘉康(1996-2007)] 期刊論文
    [劉敏(1996-2007)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISIA1997WX68200004.pdf49KbAdobe PDF923檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋